Systemic Inhibition of NF-κB Activation Protects from Silicosis

被引:60
作者
Di Giuseppe, Michelangelo
Gambelli, Federica
Hoyle, Gary W.
Lungarella, Giuseppe
Studer, Sean M.
Richards, Thomas
Yousem, Sam
McCurry, Ken
Dauber, James
Kaminski, Naftali
Leikauf, George
Ortiz, Luis A.
机构
[1] Division of Occupational and Environmental Medicine, Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA
[2] Department of Environmental and Occupational Health Sciences, School of Public Health and Informational Sciences, University of Louisville, Louisville, KY
[3] Department of Physiopathology, University of Siena, Siena
[4] Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
[5] Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
[6] Department of Thoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
关键词
D O I
10.1371/journal.pone.0005689
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Silicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNF alpha) plays a central role in the pathogenesis of silicosis. TNF alpha signaling is mediated by the transcription factor, Nuclear Factor (NF)-kappa B, which regulates genes controlling several physiological processes including the innate immune responses, cell death, and inflammation. Therefore, inhibition of NF-kappa B activation represents a potential therapeutic strategy for silicosis. Methods/Findings: In the present work we evaluated the lung transplant database (May 1986-July 2007) at the University of Pittsburgh to study the efficacy of lung transplantation in patients with silicosis (n = 11). We contrasted the overall survival and rate of graft rejection in these patients to that of patients with idiopathic pulmonary fibrosis (IPF, n = 79) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients. At the time of lung transplantation, we found the lungs of silica-exposed subjects to contain multiple foci of inflammatory cells and silicotic nodules with proximal TNF alpha expressing macrophage and NF-kappa B activation in epithelial cells. Patients with silicosis had poor survival (median survival 2.4 yr; confidence interval (CI): 0.16-7.88 yr) compared to IPF patients (5.3 yr; CI: 2.8-15 yr; p = 0.07), and experienced early rejection of their lung grafts (0.9 yr; CI: 0.22-0.9 yr) following lung transplantation (2.4 yr; CI: 1.5-3.6 yr; p<0.05). Using a mouse experimental model in which the endotracheal instillation of silica reproduces the silica-induced lung injury observed in humans we found that systemic inhibition of NF-kappa B activation with a pharmacologic inhibitor (BAY 11-7085) of IkB alpha phosphorylation decreased silica-induced inflammation and collagen deposition. In contrast, transgenic mice expressing a dominant negative IkB alpha mutant protein under the control of epithelial cell specific promoters demonstrate enhanced apoptosis and collagen deposition in their lungs in response to silica. Conclusions: Although limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that while the systemic inhibition of NF-kappa B protects from silica-induced lung injury, epithelial cell specific NF-kappa B inhibition appears to aggravate the outcome of experimental silicosis.
引用
收藏
页数:14
相关论文
共 50 条
[1]  
[Anonymous], 2005, MORBIDITY MORTALITY, V54
[2]  
[Anonymous], 2002, Am J Respir Crit Care Med, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]
[3]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI [10.1164/ajrccm.161.2.ats3-00, DOI 10.1164/AJRCCM.161.2.ATS3-00]
[4]   NF-kappa B: Ten years after [J].
Baeuerle, PA ;
Baltimore, D .
CELL, 1996, 87 (01) :13-20
[5]   The tumor necrosis factor ligand and receptor families [J].
Bazzoni, F ;
Beutler, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1717-1725
[6]  
Beckett W, 1997, AM J RESP CRIT CARE, V155, P761, DOI 10.1164/ajrccm.155.2.9032226
[7]   UNRAVELING FUNCTION IN THE TNF LIGAND AND RECEPTOR FAMILIES [J].
BEUTLER, B ;
VANHUFFEL, C .
SCIENCE, 1994, 264 (5159) :667-668
[8]   Fas ligand triggers pulmonary silicosis [J].
Borges, VM ;
Falcao, H ;
Leite-Júnior, JH ;
Alvim, L ;
Teixeira, GP ;
Russo, M ;
Nóbrega, AF ;
Lopes, MF ;
Rocco, PM ;
Davidson, WF ;
Linden, R ;
Yagita, H ;
Zin, WA ;
DosReis, GA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (02) :155-163
[9]  
BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
[10]   The Copenhagen National Lung Transplant group: Survival after single lung, double lung, and heart-lung transplantation [J].
Burton, CM ;
Milman, N ;
Carlsen, J ;
Arendrup, H ;
Eliasen, K ;
Andersen, CB ;
Iversen, M .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (11) :1834-1843